Programme

**Tuesday, June 30**

**ORAL SESSIONS 09.00-10.30**

<table>
<thead>
<tr>
<th>Oral No.</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL2</td>
<td>Plenary: The Virus: Pathogenesis, Reservoirs and Spread</td>
</tr>
<tr>
<td></td>
<td>Chairs: Luc Montagnier, Leigh Neal</td>
</tr>
<tr>
<td></td>
<td>Venue: Arena</td>
</tr>
<tr>
<td></td>
<td>Time: 09.00-10.30</td>
</tr>
</tbody>
</table>

157 From new knowledge about the virus and pathogenesis to better treatment: host factors in the pathogenesis of HIV disease: implications for therapy  
Anthony Fauci

158 Cure: myth or reality?  
Roberto Siliciano

159 Cure: myth or reality?  
Mark Harrington

160 Epidemiology of HIV-infection: new and emerging epidemics  
Quarraisha Abdool Karim

**ORAL SESSIONS 11.00-12.30**

<table>
<thead>
<tr>
<th>Oral No.</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>A21</td>
<td>Viral Assays and Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Chairs: Luigi Chieco-Bianchi, Fred S. Mhalu</td>
</tr>
<tr>
<td></td>
<td>Venue: Session Hall IV</td>
</tr>
<tr>
<td></td>
<td>Time: 11.00-12.30</td>
</tr>
</tbody>
</table>

161 Determination of HIV-1 subtypes using dried blood spots (DBS) and V3 peptide serotyping in Thailand  
Panprapa Chanchanard*; Mark de Sousa; R. Trichavaroj; P. Tien-Amporn; P. Puthakerd; A.E. Brown; T.C. Vancott; M.S. de Sousa, Thailand

162 Interactions of secretory IgA with HIV-1 gp120: Potential pitfalls of anti-HIV ELISA using saliva  
Susan Jackson*; S.J. Prince; R. Kulhavy; J. Mestecky, USA

163 HIV screening with the Elecsys automated analyser: Combined testing for anti-HIV and HIVAg within 18 minutes  
Fédéric Donie*; B. Umpère; E. Hoess; E. Faatz, Germany

164 Plasma and genital tract viral load and STDs in early HIV-infection  
Connie Celum*; K. Mayer; S. Holte; D. Dondero; S.P. Buchbinder; J. Douglas; H.W. Sheppard, USA

165 A community-based study of HIV-2 RNA load in pregnant women attending health centres in West Africa  
Pa Tamba Ngom*; S.A. Alabi; K. Aiyoshi; N. Berry; D. Odonovan; H.C. Whittle, The Gambia

166 RNA and DNA PCR for early diagnosis of infants born to HIV-infected mothers, Thailand  
Nancy L. Young*; N. Shaffer; T. Chaowanachar; N. Wanparapa; N. Waranawat; K. Chokephailubkit; T. Chodpitayasunondh; R. Chuachoowong; P. Wasiunapee; N. Kaeppunt; O. Suk Sripanich; T.D. Mastro, Thailand

**A22 Viral and Cellular Dynamics**

<table>
<thead>
<tr>
<th>Oral No.</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chairs: Dawn Everitt, Ashley Haase</td>
</tr>
<tr>
<td></td>
<td>Venue: Arena</td>
</tr>
<tr>
<td></td>
<td>Time: 11.00-12.30</td>
</tr>
</tbody>
</table>

167 Turnover of HIV  
David Ho

168 Lymphocyte dynamics and mechanisms of CD4  
Frank Miedema

169 Viral evolution  
Simon Wain-Hobson

**NOTES**
Tuesday, June 30

**ORAL SESSIONS 11.00-12.30**

**B21** Paediatrics Care and Treatment

*Chairs: Marinella Della Negra, Young Person from Opening Ceremony*

*Venue: Session Hall III*

**Time: 11.00-12.30**

170 Vitamin A supplements and mortality among HIV-positive and negative children in Tanzania

Wafaie Fawzi*, R.L. Mbise; F. Kawau; M.G. Herrera; E. Hertzmark; M. Fataki; D. Spiegelman, USA, Tanzania

171 Implementation of recommendations for the medical care of HIV-exposed infants in the first year of life, USA

Jeanne Bertolli*, R.J. Simonds; P. Thomas; S. Melville; I. Ortiz; L. Mascot; C. Wilfert; T. Rakusan; H. Hsu; Y. Maldonado, USA

172 The impact of HIV-infection on in-hospital paediatric mortality at Chris Hani Baragwanath Hospital (CHBH), South Africa

Karen Zw*, Tannmy Meyers; J.M. Pettrifor; R.N. Soderlund; J.S. Galpin, South Africa

173 First large US study of efficacy and tolerability of ritonavir in HIV-infected children

Stephen Pelton*, K. Stanley; K. McIntosh; A. Wiznia; S.A. Nachman; R. Yogev, USA

174 How often can signs, symptoms and immunological abnormalities predict perinatal HIV-infection in Brazilian infants?

Maria M. Russi-Pinhata*, M.C. Cervi; M.L. Isaac; O.A.L. Cintra, Brazil

175 Aging cohort of perinatally HIV-infected children in New York City (NYC)

Pauline Thomas*, Thomas Mundy; E.J. Abrams; K. bornschlegel; A. Brooks; T.P. Singh; J. Bertolli, USA

**B22** Complications of Protease Inhibitors

*Chairs: José Gatell, Didier Lestrade*

*Venue: Session Hall VII*

**Time: 11.00-12.30**

176 Introduction

David Cooper

177 Changes in body habitus in HIV+ women after initiation of protease inhibitor therapy

Koita Dong*; M.M. Flynn; B.P. Dickinson; J.D. Rich; K. Tashima; T.P. Flanagan; C.C. Carpenter, USA

178 Metabolic changes in HIV-infected patients treated with protease inhibitors

Enos Bernacconi*; Antonio Carota; L. Magenta; M. Pons; M. Russotti; T. Moccetti; E. Bernacconi, Switzerland

179 Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors

Rudi K. Walli*; O. Herfort; G.M. Michi; T. Demant; S. Maus; C. Deterle; F.D. Geibel, Germany

180 Discontinuation (D/C) of protease inhibitor (PI) therapy: Reasons and risk factors

Valerie E. Stone*, Lisa R. Hirschhorn; S.L. Boswell; V.E. Stone, USA

**C21** Commercial Sex: Male Clients and Female Workers

*Chairs: Cheryl Overs, Joanne Pioro*

*Venue: Session Hall V*

**Time: 11.00-12.30**

181 Issues and priorities in Latin America

Nury Pernia

182 Decline in prevalence of HIV-infection and sexually transmitted diseases and increase in condom use among female sex workers in Abidjan, Côte d'Ivoire, 1992-1997

Mamadou Oktu Diallo*, P.D. Gyus; V. Etienne-Trace; C. Anoma; M. Nioumam; Y. Hoyi; J.C. Kado; A. Tiemele; I.M. Coulibaly; A.E. Greenberg; M. Laga; S.Z. Wilkot, Côte d'Ivoire

183 Peer education awareness among commercial sex worker in Pokhara, Nepal

Krishna P. Bista*, R. Adhikari; P. Aryal; A. Erpelding, Nepal

184 Promoting condom use among female sex workers in natural settings in Yunnan, China

Ziryou Wu*; J.P. Zhang; Y.S. Wang; M.H. Jia; Y.H. Kang; Y.J. Duan; L.L. Dong, China

185 Criteria for evaluation of education given to clients of sex workers

Lucie Van Mens*, P. Vangelder, The Netherlands

186 Scaling up of interventions through community-based organisations

Rekha Chowdhury*; S. Jana; S. Chowdhury; L. Mali; P. Singh; M. Mitra, India

**C22** Treatment Impact, Biological Factors and Disease Progression

*Chairs: Tom Mboya, Martin Schechter*

*Venue: Session Hall VI*

**Time: 11.00-12.30**

187 Long-term survivors under observed effectiveness of highly active antiretroviral therapy

Alvaro Munoz*, G. McFarlane; L.K. Schrager; J.W. Mellors; J.B. Margolick; J.P. Phair; R. Detels, USA

188 Estimating the effect of treatments on AIDS incidence in Australia

John M. Kaldor*, M.G. Law; J. Cui, Australia

189 Survival following HIV seroconversion: Evidence of a recent change?

Kholoud Porter, UK

190 Long-term nonprogressors (LTNP): Prevalence and predictors through 18 years of follow-up

Eric Vittinghoff*, M.J. Feinberg; T. Elbeke; S. Staprans; M. Carrington; G. Collar; S. Buchbinder, USA

191 Viral load and CD4 cell count in injecting drug users (IDUs) newly infected with HIV-1 subtypes B and E, Bangkok

Timothy Masto*, D. Kitayaporn; N.L. Young; S. Vanichseni; S. Raktham; L. Sriusawanvil; S. Subbarao; P. Mock; C. Wasi, Thailand

192 Geographic variation in disease progression in 664 HIV-1 seroconverted injecting drug users in Europe?

Mana Prins, The Netherlands
**JUNE 30**

**Tuesday, June 30**

**CONFERENCE WORKBOOK**

**ORAL SESSIONS**

**11.00 - 12.30 13.00 - 14.30**

---

**C23 New Developments in Public Health Surveillance**

**Chairs:** Cornelius Baker, Irena Klavs

**Venue:** Satellite Hall 2000

**Time:** 11.00 - 12.30

193 Broadening the tools for public health surveillance - a wider range of indicators

Bernhard Schwartländer

194 Ongoing changes in surveillance systems in Europe including Eastern Europe

Andrea Infuso

195 Moving to national HIV reporting (USA)

Larry Costin

196 Population-based versus sentinel site surveys in Zambia

Rosemary Musonda

---

**D21 Bridging Session: Implications of Therapies for Developing Countries**

**Chairs:** Teguest Guerma, Jairo Pedraza

**Venue:** Session Hall I

**Time:** 11.00 - 12.30

197 Introduction and overview

Awa Coli-Sedik

198 NGO networking for access to drugs in West Africa (review of sub-regional initiatives)

Allou Sylla

199 Investigation of access to HIV-related treatments in Asia through NGO collaborations

Tuti P Merati

200 Government perspective on access to care in Brazil and Latin America

Pedro Chequer

201 A cross country perspective

Mead Over

202 Implication of the private sector: access to care for employees

Sean Cheevers

---

**D22 Gender and Power**

**Chairs:** Chumpon Apisuk, Dusilley Cannings

**Venue:** Session Hall II

**Time:** 11.00 - 12.30

203 Reducing gender-related barriers in HIV prevention efforts: Findings from ICRW’s women and AIDS research program

Ellen Weiss*, B. Nastasi, USA

204 Gender issues in HIV prevention for heterosexual men

Angela Esher*, A. Menezes; G. Santos; E. Santos Filho; R. De-Lima, Brazil

205 Cultural beliefs: barriers to sex discussion among married couples and its implications in STD/HIV/AIDS prevention in Malawi

Antony Chaima*, D. Zamba, Malawi

206 Gender and STD/HIV risk in nine populations in Nepal: Challenging the ideal of a woman of “Good Character”

Dhana Mallia Shrestha*, W. B. Thompson; L. Weedon, Nepal

207 Power echoes: The impact of gendered power relations on HIV/AIDS risk and risk reduction as echoed in survey responses

Teresa Swiezey*, C. M. Otero; F. Asensi; A. Gonzalez-Molina, Spain

208 Whose turn tonight? An appropriation of the circumstances of condom use (purchase, proposal, donning) by gender

Brenda Spencer*, A. Jeannin; F. Dubois-Arber, Switzerland

---

**Skills Building Workshops 11.00 - 14.30: see page 76 for details**

---

**A23 Mother-to-Child HIV Transmission: Biological Determinants**

**Chairs:** Hoosen Coovadia, Gabriella Scarlatti

**Venue:** Session Hall III

**Time:** 13.00 - 14.30

209 Viral dynamics in neonatal macaques after oral inoculation with HIV-2287: Implications for human transmission

Amul Martin Herz*, C. Sherbert; A. Schmidt; M. B. Agy; M. N. Robertson; P. D. Greenberg; W. R. Morton, USA

210 Class I MHC polymorphism and mother-to-child HIV-1 transmission in Kenya

Kelly S. Macdonald*, Jose Castello; E. Embree Joanne; Simon Njenga; J. D. Nagelkerke Nicolas; Irene Ngatia; Zena Mohmmed, Canada

211 Co-receptor usage of HIV-1 isolates of different subtypes derived during pregnancy

Eva Maria Fenyo*, D. Vidovic; C. Tscherning; D. R. Littman; J. Albert, Sweden

212 Distinctive pattern of DC3 T cell clonal dominance identified in HIV-infected children by CD3 length analysis of T cell receptor (TCR) V beta repertoire

Sue Than*, Savita Pahwa; M. Kharbanda; C. Vivek; C. Surenua; S. Bakshy; S. Pahwa, USA

213 The expression of CD38 and DR are markers of immune activation and disease progression in HIV+ children

Rafael Sirena*, A. Bayona F. Carbonell; D. Perez-Tamari; M. C. Otero; F. Asensi; A. Gonzalez-Molina, Spain

214 Influence of maternal HIV-1 and HIV-2 on child survival in The Gambia


215 CDR3 genotype and HIV-1 infection in perinatally-exposed infants

Nieves Villalba*, M. Perez-Ormeda; M. Dejose; A. Gonzalez-Molina; R. Sirena; T. Espinol; V. Soriano, Spain

---

**NOTES**

---

---

---
**A24 Cytokines**

Chairs: Ferdinando Dianzani, Bruno Spire

Venue: Session Hall IV

**Time:** 13.00–14.30

**216** Detection of memory T cells in HIV+ individuals: Cytokine producing lymphocyte precursors (CPLp)

Kendall A. Smith*; G. Chiocchia; F. Pilario; E.L. Jacobson; R. Emert, USA

**217** Alteration of intracellular cytokine synthesis in CD4+ and CD8+ cell subsets during progression of HIV disease

Eva Barabási; N.K. Nagy; G.C.R. González; H.A. Horváth, Hungary

**218** Differential effects of IL-4 on HIV-1 expression suggest a role in viral phenotypic switch and disease progression

George N. Pavlakis*; A. Valintin; W. Lu; M. Rosati; R. Schneider; J. Albert; A. Karlsson, USA

**219** Impact of potent anti-HIV therapy on T helper cell homeostasis and type 1 cytokine synthesis

Eric Ledru*; H. Lacouer; R. Rave; O. Patey; M.L. Giancola, France

**220** Production of type 1, type-2 cytokines and β-chemokines in HIV+ patients: Influence of HAART

Andrea de Luca*; M.L. Giancola; A. Giancola; A. Ammassari; R. Muni; L. Ortona, Italy

**221** Patterns of cytokine production analysed at single cell level during highly active antiretroviral therapy (HAART)

Ana Sousa*; Rui Victorino; A.F. Chaves; A.C. Graça; M. Doroana; F. Antunes; R.M.M. Victorino, Portugal

---

**B24 Bridging Session: Life Beyond Treatment**

Chairs: Ruedi Luthy, Ruth Sims

Venue: Session Hall VII

**Time:** 13.00–14.30

**222** Palliative care in industrialized countries

Peter Selwyn

**223** Care beyond treatment in developing countries

Ursula Sharpe

**224** Spiritual aspects

Alonkot Tikkapanyo

**225** New emotional and psychosocial issues for patients and providers in the era of HAART

Sandra Jacoby Klein

**226** Legal aspects (living wills, return to work, etc.)

Florian Hübner

---

**B24 Antiretroviral Resistance**

Chairs: Victoria A. Johnson, Filippo Von Schloesser

Venue: Arena

**Time:** 13.00–14.30

**227** Review of Lago Maggiore Resistance Meeting

John Mellors

**228** Frequency of transmission of drug-resistant variants in individuals with primary HIV-1 infection

Sabine Yerly*; G. Schockmel; J.P. Bru; B. Hirschel; L. Perrin, Switzerland

**229** HIV genotypic predictors of antiviral response to saquinavir (SQV)/ritonavir (RTV) therapy in patients who have failed prior protease inhibitors (PIs): A clinical cohort study

Andrew Zolopa*; R. Shafer; A. Warford; J. Montoya; O. Katzenstein; T. Merigan, USA

**230** Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1,000 clinical HIV-1 isolates

Kurt Hertogs*; B. Larder; J. Albert; V. Miller; S. Kemp; F. Peeters; R. Pauwels, Belgium

**231** Correlation of phenotypic resistance and clinical efficacy of abacavir in a phase III pediatric study

Susan C. Danehower*; C.D. Mitchell; C.A. Gilbert; A. Keller; M.L. Smiley; S.V. Hetherington; E.R. Lanier, USA

**232** Detection of genotypic drug resistance to antiviral nucleoside inhibitors in short-time pretreated and drug-naive HIV-1 infected patients as predictor of treatment failure in high-acting antiretroviral therapy (HAART)

Anja Mauzher*; K. Arasteh; V. Simon; C. Möcklinghoff; A. Moll, Germany

---

**C24 Interventions for Vulnerable Women**

Chairs: Joyce Hunter, Malu Quintos

Venue: Session Hall V

**Time:** 13.00–14.30

**234** Women’s health promotion – STD/AIDS prevention and control: Integration of activities

Ana M. A. Pluciennik*; L. S. Santos; L.H. Matida; C. Megide, Brazil

**235** Setting the stage for a family intervention: Results from focus group studies of Puerto Rican mothers and adolescent daughters

Ruth Nina-Estrella*; G. Rivera-Rivera; I. Cunningham; A. Gullon-Rivera; K. Sikkema; J.A. Kelly, Puerto Rico

**236** Sexual coercion and HIV risk perception in rural Uganda

Lynn Paxton*; R. Siengoni; F. Nalugoda; K. Sikkema; J.A. Kelly, Uganda

**237** Working with women whose male partners are homosexually active

Sara Lubowitz, Australia

**238** Reducing harm: The effects of childhood abuse on negotiating HIV risk reduction

Janna Cordeiro*; C. E. Sterk; K. Springer; K. Elifson, USA

**239** Outcomes of a community-level HIV prevention intervention for women

Kathleen Sikkestra*; J.A. Kelly; L.J. Solomon; R.A. Roffman; V.A. Cargill; R.A. Winett; T.L. Mcauliffe, USA

---

Pathway Symbols: Gender Youth and Children
**ORAL SESSIONS**

**C25** Migration and HIV

**Chairs:** François Fleury, Ali Shouket

**Venue:** Session Hall VI

**Time:** 13.00–14.30

240 A critical assessment of HIV/AIDS prevention interventions for people on the move in sub-Saharan Africa

- Thomas Painter, USA

241 HIV-prevention in complex emergency countries

- Idriss Sow*, K. Shibib, E. Kita, Switzerland

242 Mobile AIDS Booths (MABs) – A novel intervention for migrating labour and their families

- Sunya Rao Kutikuppala*, K.S.W. Raju; R.D. Pilli; K. Prakash Babu, India

243 Border crossing HIV/AIDS prevention in different European states - A comparison

- Michael F. Krause*; E. Steffen; Dr. W. Heckmann, Germany

244 Implications of complex emergencies, uprooting and forced migration on risk of HIV/AIDS: The case of Bosnia and Herzegovina

- Manuel Carballo*; S. Puvacc; D. Zeric, Switzerland

245 AIDS prevention among migrant sex workers in Geneva

- Joanna Piotro, Switzerland

**NOTES**

**C26** Post-Exposure Prophylaxis

**Chairs:** Elisabeth Bouvet, Helene D. Gayle

**Venue:** Satellite Hall 2000

**Time:** 13.00–14.30

246 Tolerability of antiretroviral agents used by health care workers (HCWs) as postexposure prophylaxis (PEP) for occupational exposures to HIV

- Adelisa Panlilio*, D.M. Cardo; S. Campbell; P. Srivastava; Nash Surveillance Group, USA

247 Post-exposure prophylaxis for occupational and sexual exposures to HIV: experience in a London hospital

- Philippa Easterbrook*; D. Hawkins; F. Boag; A. Pearce; H. Vaile; C. Richardson, UK

248 French physician’s experiences and attitudes about non-occupational post-exposure prophylaxis (PEP)

- Anne Laporte*; F. Lamontagne; J. Saint-Maurice; F. Lot, France

249 Time-ordered indicators: Useful and efficient tools for steering the national HIV-prevention campaign in Germany

- Wolfgang H. Mueller*; G. Christiansen; E. Pott; J. Toeppich, Germany

**D23** Evaluation Methodology

**Chairs:** Maxine Ankrah, D. Wilkinson

**Venue:** Session Hall I

**Time:** 13.00–14.30

252 Cochrane collaborative review group on HIV-infection and AIDS: systematic reviews of HIV and AIDS prevention and treatment

- George Rutherford*; G.E. Kennedy; L.A. Bergo, USA

253 HIV-prevention in complex emergency countries

- Salaam Semaan*; D.C. Des Jarlais; E.D. Sogolow; G. Ramirez; M. Sweat; L.M. Norman; R.H. Needle, USA

254 A review of HIV interventions with adult homosexually active men

- Theresa M. Enner*; P. Gardos; A.A. Ehrhardt; D. Seal, USA

255 Methodological issues in multidisciplinary research in a data-poor third-world community

- Jacqueline Desbarats, Kampuchea

256 Improving HIV/AIDS prevention interventions through program evaluation at the community level

- Esther Sofer, L.L. Otto-Salaj, USA

257 Does measured behavior change reflect change in STD/HIV risk?

- Thomas Peterman*; L. Lin; G. Bolan; J. Zenilman; J.M. Douglas; J. Rogers, C.K. Malotte, USA

258 Methodologic issues in outcome measures of HIV prevention research: Behaviors of serodiscordant heterosexual couples

- Heather Huszti*; J.T. Parsons; B.E. Gage, USA

259 Time-ordered indicators: Useful and efficient tools for steering the national HIV-prevention campaign in Germany

- Wolfgang H. Mueller*; G. Christiansen; E. Pott; J. Toeppich, Germany

**D24** Coping Strategies: Individuals, Families and Organisations

**Chairs:** Jonathan Grimshaw, Mary Jane Musungu

**Venue:** Session Hall II

**Time:** 13.00–14.30

260 Support for patients with HIV/AIDS by training their families in integral home care (Mexico)

- Sergio Hugo Palma Guzman*; R.M. Duarte Sotelo; G. Gomez Tinoco, Mexico

261 Prevention of stresses in families of HIV-infected patients

- Natalya Pelisnaya*; N.L. Lukyanova, Ukraine

262 Sex after diagnosis: What support services can be provided?

- Winit Tienudom, Thailand

263 HIV/AIDS and employment creation

- Prisca Nya Kutombwa, Zimbabwe

264 Community-based home-care and women’s empowerment

- Sonja Weinreich*; M. Phalan; M. Tarakings; H. Nagel, Zambia

**NOTES**
### A25  Viral and T Cell Dynamics

**Chairs:** Haynes W. Sheppard, Frank De Wolf  
**Venue:** Session Hall III  
**Time:** 15.00–17.00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>USA</th>
<th>Canada</th>
<th>Israel</th>
<th>Switzerland</th>
<th>Canada</th>
<th>Israel</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>265</td>
<td>Viral dynamics in HIV-infected patients: correlation with host-specific factors and virological failure</td>
<td>Hulin Wu*, D.R. Kuritzkes, M.S. Clair, G. Spear, E. Connick, A. Landay, M.M. Lederman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>266</td>
<td>Slow proviral DNA reduction in patients on triple drug therapy and rapid viral rebound upon stopping therapy</td>
<td>Richard Paul Harrigan*, J.S.G. Montaner, C. Christopherson, S. Kwok, J. Sninsky, M. Harris, B. Conway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>267</td>
<td>Modeling the sources for persistent HIV load in patients receiving HAART - Evidence for a drug sanctuary compartment</td>
<td>Avidan U. Neumann*, A. Mallet, V. Calvez, T. Li, R. Tubiana, C. Katlama, B. Autran</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>268</td>
<td>Increased turnover of both CD4 and CD8 T-cells in HIV-1 infection until end stage disease</td>
<td>Nicolas Sachsenberg*, A.S. Perelson, S. Yerly, G.A. Schockmel, D. Leduc, B. Hirshel, L. Perrin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>269</td>
<td>Dynamic changes in naive and activated T cells in blood and lymph nodes in patients receiving highly active antiretroviral therapy (HAART)</td>
<td>Clive Gray*, J. Lawrence, J. Schapiro, M. Vierra, T.C. Merigan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>271</td>
<td>Telomere length and telomerase analysis in blood and lymph nodes provide no evidence for increased CD4+ T-cell production in HIV-1 infection</td>
<td>Katja C. Wothers*, S.A. Otto, A.J. Neost, G.B.A. Wisman, S. Fleury, R.J. de Boer, F. Miedema, The Netherlands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### A26  HIV Pathogenesis

**Chairs:** Zui Bertwich, Janis Giorgi  
**Venue:** Session Hall IV  
**Time:** 15.00–17.00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>USA</th>
<th>Canada</th>
<th>Israel</th>
<th>Japan</th>
<th>USA</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>273</td>
<td>Latent viral reservoirs in patients on highly active antiretroviral therapy: Implications for virus eradication</td>
<td>Diana Fina*, J. Gallant, K. Chadwick, J. Margolick, R.F. Siliciano</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>274</td>
<td>Indirect mechanism of bystander cell death of CD8 T cells induced by CD4 crosslinking (XL) of CD4 T cells</td>
<td>Savita Palavra*, M. Tateyama, T. McChesney, S. Than</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>275</td>
<td>Macrophages-mediated CD8+ T cell killing via OX40/ENV interactions during HIV-infection</td>
<td>Georges Herbein*, U. Mahlknecht, W.A. O'Brien, E. Verdin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>276</td>
<td>Control of HIV-1 proliferation and pathogenesis with host factors in the hu-PBL-SCID mouse system</td>
<td>Yuetsu Tanaka*, R. Tanaka, Y. Kumazama, Y. Koyanagi, N. Yamamoto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>277</td>
<td>HIV-1 subtypes differ in time to AIDS</td>
<td>Phyllis Kanki*, D. Hamel, J. L. Sankale, I. Thior, R.G. Marlink, M. Essex, S. Mboop, USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>278</td>
<td>Mechanisms of HIV transmission through epithelial cell barriers</td>
<td>Charlene S. Dezutti*, R.B. Lal, USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>279</td>
<td>Seminal cell-associated viral transcriptional activity and the level of seminal chemokines in the shedding of HIV-1 in semen</td>
<td>Phalguni Gupta*, B.K. Patterson, C.R. Rinaldo, M. Ding, K. Kuuka, W. Buchanan, L. Kingsley, USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>280</td>
<td>Influence of interleukin-15 on apoptosis and proliferation of T lymphocytes of HIV-infected individuals: Comparison with interleukins-2 and -12</td>
<td>Honami Naora*, M.L. Gougeon, France</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### B25  Adherence to Antiretroviral Therapy

**Chairs:** Arjen Broekhuizen, Michael Kazatchkine  
**Venue:** Session Hall VII  
**Time:** 15.00–17.00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>USA</th>
<th>Canada</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>281</td>
<td>Overview</td>
<td>Margaret Chesney</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>282</td>
<td>Adherence considerations in primary care, monitoring</td>
<td>Cassy Workman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>283</td>
<td>Various HIV communities, communication, future</td>
<td>William Woodward</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>284</td>
<td>Living with the regimen</td>
<td>Paul Ward</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>285</td>
<td>Compliance issues in developing country cultures</td>
<td>Godfrey Sikipa</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### ORAL SESSIONS

**B26**

**ART II: Clinical Trials**

**Chairs:** Brian G. Gazzard, Vanessa Johnson  
**Venue:** Arena  
**Time:** 15.00–17.00

286 **Combination abacavir (1592, ABC)/amprenavir (141W94) therapy in HIV-1-infected antiretroviral naïve subjects with CD4+ counts 400 cells/μl and viral load 5000 copies/ml**  
**Pierre-Alexandre Bart**; G.P. Rizzardi; S. Gallant; P. Meylan; W. Spren; H. McDaile; U.K. Pantaleo, Switzerland

287 **Hydroxyurea in combination regimens for the treatment of antiretroviral naïve, HIV-infected adults**  
**Sergio Lupoto**; Marianne E. Federici; P. Cahn; J. Cassetta; R. Pastor; G. Ruiz-Palacios; J.S.G. Montaner; T. Kelleher, USA

288 **Salvage of multi-drug resistant HIV-infection with D4T/3TC/hydroxyurea**  
**Steven Miles**; R.E. Winters; P. Ruane, USA

289 **Assessment of viral load and CD4/CD8 ratio in blood and lymph nodes in patients treated with 4ART, ddI/2 hydroxyurea (HU)**  
**Sabine Yerly**; O. Rutschmann; F. Marchal; M. Opravil; B. Hirschel; L. Perrin, Switzerland

290 **Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals**  
**Graeme Moyle, UK

291 **Treatment of ritonavir (RTV)/saquinavir (SQV) versus RTV/SQV/Stavudine (d4T) (The Prometheus Study): Preliminary results**  
**Elisabeth H. Gisolf**; F. de Wolf; J. Pelgrom; F. van Wanzeele; M. Popescu; A. Japour; S.A. Danner; R. van Leeuwen, The Netherlands

292 **Long-term evaluation of saquinavir soft-gel capsule or indinavir as part of combination therapy (CHEESE Study)**  
**Jan Boerkoel**; Charles A.B. Boucher, The Netherlands

293 **The safety, tolerance, pharmacokinetics, and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, in a phase I/II study**  
**Yenyun Wang**; C.M. Tutton; M.T. Borin; C.L. Daenzer; H. Li; R.M. Wurtz; A.A. Piergies; W.W. Freimuth, USA

### C27 Bridging Session: Vaccines: Overcoming Obstacles to Human Trials

**Chairs:** Seth Berkley, José Esparza  
**Venue:** Session Hall V  
**Time:** 15.00–17.00

294 **Introduction**  
José Esparza

295 **Overview of trials underway and planned**  
Carole Heilman

296 **Ethics of vaccine research and development**  
Ruth Macklin

297 **Trials in developing countries**  
Natth Bhamarapravati

298 **Community involvement and mobilisation**  
Ronaldo Musaaua de Lima

299 **The role of industry**  
Jean-Jaques Bertrand

300 **The economics of AIDS vaccines and prevention**  
Callisto Madavo

301 **Closing statement**  
Seth Berkley

302 **Questions from the floor**

### C28 Mobile Populations and HIV: Vulnerability, Risk and Human Rights

**Chairs:** Mary Haour-Knipe, Robert Tezzo  
**Venue:** Session Hall VI  
**Time:** 15.00–17.00

303 **HIV and human mobility: an epidemiological overview**  
**Alix Ashen

304 **War, refugees and HIV**  
**Millicent Obaso

305 **Mobile populations and risk situations in Mexico and Central America**  
**Mario Bronfman

306 **Mobile populations and risk situations in Southeast Asia**  
**Irene Fernandez

307 **Labour migration and HIV epidemics in Africa**  
**Joseph Decosas

308 **Human rights issues**  
**Norbert Gilmore

309 **Human rights issues from the point of view of migration activists**  
**Reda Sadki

### D25 Mother-to-Child HIV Transmission: Infant Feeding

**Chairs:** Eric Mercier, Catherine Oyige  
**Venue:** Session Hall I  
**Time:** 15.00–17.00

310 **Breastfeeding programmes and HIV questions**  
**Felicity Savage-King

311 **IOW Reproductive Project**  
**Lindy Francis

312 **Psychosocial aspects of breastfeeding**  
**Linda Richter

313 **Breast feeding in the HIV/AIDS era in Zimbabwe**  
**Caroline Maposhere, Zimbabwe

314 **Attitudes and behaviour of HIV-infected women on infant feeding**  
**Glenda Gray

315 **Strategies for preserving breastfeeding**  
**Mary Bassett

316 **Breast or bottle? A cost-effectiveness evaluation of formula feeding for the prevention of postnatal transmission of HIV in an urban South African setting**  
**Neil Söderlund**; G.E. Gray; K.J. Zwi, South Africa

317 **Discussant**  
Catherine Peckham

### NOTES

---

---

---

---

---

---

---

---
Tuesday, June 30

**ORAL SESSIONS  15.00-17.00**

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Chairs</th>
<th>Venue</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>D26</td>
<td>Bridging Session: International Funding and Policy: Closing the Gap?</td>
<td>Dominique Hausser, Marina Mahathir</td>
<td>Session Hall II</td>
<td>15.00-17.00</td>
</tr>
</tbody>
</table>

- 318 Health reform and funding by international organisations and/or bilateral agreements
  Ousmane N’gom
- 319 Funding priorities for HIV/AIDS in economic crisis (i.e. faced with budget cuts)
  Prawase Wasi
- 320 Funding a national policy against the HIV/AIDS epidemic
  Yin Dakui
- 321 The fund for therapeutic solidarity
  Bernard Kouchner
- 322 Economics, demography and policy: encouraging governments to confront AIDS
  Callisto Madavo
- 323 Discussant
  Jonathan Mann

**Skills Building Workshops 15.00-18.30: see page 77 for details**

CS 6  Treatment Access by the South for the South

**Venue:** Session Hall I  
**Time:** 17.30-20.00

This session aims to review the state of access to treatment in a number of developing countries, including efforts being made by various agencies, and develop recommendations for a plan of action. The session will involve a short overview of the issues; short presentations on the state of access to treatment within each region and efforts to address problems; and small group work on practical solutions.

**Chairs**
Usa Duongsaa, AIDSNET, Thailand
Marcelo Soares Serra, Praca Serzedelo Correa, Brazil

**Speakers**
- Overview
  Noerine Kaleeba, Community Mobilisation Advisor, UNAIDS
- Issues for Latin America
  Jorge Beloqui, Brazil
- Issues for Africa
  Moustapha Gueye, Programme Manager, Enda Sante, Senegal
- Issues for Asia
  Tuti Merati, APGASO, Indonesia
- Issues for Eastern Europe
  Zdenek Kurka, CREJDM, Czech Republic

**Treatment Access Plan Facilitators**
- Plan for Latin America
  Ezio dos Santos Filho, Executive Coordinator, Grupo Pela Vidda/RJ, Brazil
- Plan for Africa
  Miriam Maluwa, Human Rights Adviser, UNAIDS
- Plan for Asia
  Susana Murni, Spiritia Foundation, Indonesia
- Plan for Eastern Europe
  Kasia Malinowska-Sempruch, UNDP, Poland

CS 7  Developing National and International Networks

**Venue:** Session Hall II  
**Time:** 17.00-20.00

Interactive panel discussion, focusing on the role of networking in strengthening the response to HIV/AIDS through advocacy and lobbying. The session has been designed to ensure that the audience is informed of the tenets of networking; becomes familiar with different networking approaches; and has an opportunity to discuss strategies and barriers to effective networking. Materials and documents to aid networking will be briefly reviewed, with an emphasis on the Networking Guide, produced by the International Council of AIDS Service Organisations (ICASO).

**Chairs/Facilitators**
Shaun Mellors, GNP+ Coordinator, Netherlands
Jacqueline Coleman, NACASO, USA

**Resource People**
Richard Burzynski, Executive Director, ICASO, Canada
Abdellah Bacha, President AfriCASO, Senegal
Annie Madden, International Drug Users Action Group, Australia
Iren Bischofberger, RN, Board Member, European Association of Nurses in AIDS Care (EANAC), Switzerland
Mabel Blanco, Lacaso, Argentina

Pathway Symbol:  Policy
**CS 8  Community Development and the Private Sector: Are they Compatible Partners?**

**Venue:** Session Hall III  
**Time:** 17.30-20.00

Roundtable discussion with leaders in the business sector who are involved in AIDS-related activities, involving initial statements by panel members, moderated discussion between participants, and discussion with the audience.

**Chairs**  
José Llados, Manager, Donor and Corporate Relations, UNAIDS  
Marina Mahathir, President, Malaysian AIDS Council, Malaysia

**Speakers**  
- Overview and Economic Situation  
  Mead Over, Senior Economist, Policy Research Department World Bank
- Tools for partnership  
  Ros Tennyson, Director, Learning and Leadership Programmes, Associate Director, Prince of Wales Business Leaders Forum, UK
- Private sector and community partnerships in South Africa  
  Sevil Hartshorne, Rotary, Small Business Managing Director, South Africa
- Popular culture, advertising and education  
  Philippe Nordman, Chairman, Sid-Aide, Geneva
- Workplace policies and community initiatives in Latin America  
  Sergio Mario Villares, Chief Executive, Industries Villares S.A. (TBO), Brazil
- Involving the business sector in Southeast Asia  
  Tony Pramalutra, Group Marketing Controller, Thailand Business Coalition on AIDS, Thailand
- Internet and mobilisation related to HIV  
  Catherine Taylor, Group Marketing Controller, London International, UK
- The role of unions in community development and HIV  
  Trevor Sharp, Building Trades Group Drug and Alcohol Committee, Australia

---

**CS 9  Storytelling: Personal Tales of People Living with HIV/AIDS**

**Venue:** Session Hall IV  
**Time:** 17.30-20.00

Panel speaking about their personal experiences and/or the active role of such stories in influencing others, followed by facilitated discussion on the lessons to be learnt from such approaches.

**Chairs/Facilitators**  
Kim Blankenship, Yale AIDS Program, USA  
Martina Clark, NGO Liaison Officer, UNAIDS

**Speakers**  
- Developing memory books to leave for children  
  Nabaggala Scovia Kasolo, Uganda
- Coping as an elite in the workplace  
  Richard Constant Oku, Uganda
- Working for and with the community  
  Pimjai Intenmoon, Thailand
- PWA mothers coping with family issues in an urban environment  
  Hortencia Donaldson, The Blooming Society, USA
- Your life story by someone else: growing up with HIV in the 90s  
  Carsten Schatz, POSITIV e. V. National Network of PWAs, Germany
- Influence of positive people going public on HIV policy and prevention  
  Susan Paxton, Asia Pacific Network PLHWA, Australia

---

**CS 10  Culture: Art and Artists Responding to AIDS**

**Venue:** Session Hall VI  
**Time:** 17.30-20.00

Interactive roundtable, with four short performances, followed by four speakers and then general discussion.

**Chairs**  
Dennis Altman, School of Politics, La Trobe University Australia  
Kate Shindle, 1998 Miss America, USA

**Performers**  
- Puppets Against AIDS, South Africa  
- DramAïDE, South Africa  
- Shrti Dance, Bangladesh  
- Komol Gandhar, India

**Speakers**  
- Art evolving with an epidemic  
  Frank Wagner, Neue Gesellschaft für Bildende Kunst, Germany
- RAPSO: singing youth as educators  
  Godfrey Sealy, Trinidad
- Drama and prevention  
  Lynn Dalrymple, South Africa
- Cultural traditions and AIDS  
  Jovesa Speith, Programme Manager, AIDS Task Force of Fiji
- The use of theatre in social education  
  Gordon Bilbrough, Manager, Puppets Against AIDS, South Africa
<table>
<thead>
<tr>
<th>SB 17</th>
<th>Le développement de compétences en matière d'éthique et de droits humains à l'échelle locale (en français)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room E</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>

Les personnes vivant avec le VIH/SIDA sont souvent confrontées à des discriminations dans de nombreux aspects de leur vie quotidienne. Cet atelier se servira d’études de cas pour tenter de trouver des réponses à ces discriminations. D’orientation pratique, cet atelier fournira des solutions concrètes aux personnes qui, sans être nécessairement juristes ou expertes en droits de la personne humaine, sont intéressées par le militantisme dans ces domaines. La question sera abordée d’après les perspectives des pays en voie de développement, ainsi que d’après celles des pays développés.

Facilitated by: Abdelkader Bacha, ENDA, Senegal; Jean Marie Talom, Réseau sur l’éthique, le droit et le VIH/SIDA (REDS), Cameroon; Khadija Berrebeh, Association tunisienne de lutte contre les MST/SIDA, Tunisia; Patrick Levy, Israel AIDS Task Force, Israel

<table>
<thead>
<tr>
<th>SB 18</th>
<th>Creación de recursos locales para tratar temas éticos y de derechos humanos (en español)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room F</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>

Las personas con VIH/SIDA pueden enfrentarse a situaciones discriminatorias a lo largo de sus vidas. Mediante el estudio de casos, este taller estará orientado a la búsqueda de soluciones. Este taller práctico, donde se buscan soluciones, está especialmente dirigido a todas aquellas personas que no cuentan con ninguna experiencia en temas relacionados con los derechos legales y derechos humanos, pero que quieran convertirse en activistas dentro de este campo. Se abordarán las perspectivas de los países desarrollados y de los países en vías de desarrollo.

Impartido por: Edgar Carrasco, ACCSI, Venezuela; Rita Arauz, Fundación Nimiahutzin, Nicaragua; Silvia Paneblanco Labbe, Salud y Justicia, Mexico

<table>
<thead>
<tr>
<th>SB 19</th>
<th>Designing and Sustaining Peer Education Programmes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room G</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>

Peer education programmes can be truly effective when they are properly designed, structured and monitored. Join us to share ideas on how to: conduct a rapid assessment; map project sites; recruit and train peer educators; develop simple, structured, interactive outreach activities; combine peer education with systematic condom distribution; and monitor and evaluate programme efforts, both for self-improvement and to convincingly demonstrate value for money and “real-world” impact. This workshop is aimed at educators and programme planners and managers.

Facilitated by: Patience Chirenda, University of Zimbabwe, Zimbabwe; Julian Jayaseelan, Pink Triangle, Malaysia; Leslie Wagman, Vancouver-Richmond Health Board, Canada; Bella Luk; AIDS Concern, China

<table>
<thead>
<tr>
<th>SB 20</th>
<th>Using Participatory Community-Based Research to Improve HIV Programmes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room H</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>

Prevention programmes must move beyond raising awareness in order to challenge people to examine their own behaviour and reduce their risk. This workshop will use case studies to help participants design a participatory research strategy. It is aimed at people interested in better integrating their target groups into prevention activities.

Facilitated by: Brent Allan, AIDS Council of New South Wales, Australia; Madhu Deshmukh, DFID, India; Dan Allman, University of Toronto, Canada; Mary Jane Musungu, TASO, Uganda

<table>
<thead>
<tr>
<th>SB 21</th>
<th>Practical Epidemiology: How to Survey and Report Data to Support Your Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room I</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>

Participants will become familiar with basic survey design principles, methods of interpreting data and reporting data to support activities. Using research questions suggested by participants, a questionnaire will be designed. Participants will explore how data gathered in an epidemiological survey can support a new or existing programme. This workshop is open to participants with little or no epidemiological experience and background but who are interested in learning basic techniques.

Facilitated by: William Osei, Saskatchewan Department of Health, Canada; Noleen Dube, University of Zimbabwe, Zimbabwe; Amnome Alakoye, Research Triangle Institute, USA

<table>
<thead>
<tr>
<th>SB 22</th>
<th>L’Internet: accès au réseau et bon usage (en français)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room K</td>
</tr>
<tr>
<td>Time:</td>
<td>11.00–14.30</td>
</tr>
</tbody>
</table>


Dirigé par: Francisco Mingorance; Tim France; Norbert Ayer, Fondation du Présent, Suisse and M. David Haerry, Sida Info Doc Suisse, Suisse

<table>
<thead>
<tr>
<th>SB 23</th>
<th>Extending Community Prevention and Care Programmes to Incorporate Orphan Responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Room E</td>
</tr>
<tr>
<td>Time:</td>
<td>15.00–18.30</td>
</tr>
</tbody>
</table>

As AIDS continues to devastate families and communities, planning and responding to the needs of children orphaned by AIDS is necessary. Join us to discuss how to plan and integrate programmes to support orphans into existing community HIV prevention and care activities. This workshop is aimed at those working in HIV prevention and care.

Facilitated by: Ravinder Kathuria, University of Zambia, Zambia; Sophia Mukaso-Monico, TASO, Uganda
SKILLS BUILDING WORKSHOPS

SB 24  Gestion pratique des MST selon les symptômes (en français)
Venue: Room F
Time: 15.00-18.30

Dans un contexte aux ressources limitées, la gestion pratique des MST selon les symptômes permet un contrôle simple et efficace des MST. Les participants pourront partager les problèmes rencontrés dans la mise en œuvre de ce genre d’approche. Ils pourront en outre s’ aider mutuellement à identifier des solutions possibles et développer une documentation systématique sur les cas pouvant les aider à affiner leurs diagnostics et leurs directives de traitement. Cette session est destinée au personnel clinique.

Dirigé par: Jens van Roey, UNAIDS, Netherlands/Switzerland

SB 25  Utilización de los métodos interactivos de capacitación (en español)
Venue: Room G
Time: 15.00-18.30

Cómo enseñar las materias técnicas o científicas a educadores paritarios, padres o trabajadores sociales? Cómo dar un tono personal a las estadísticas y las investigaciones al presentarlas ante instancias políticas, ante un consejo parroquial o una junta escolar? Cómo hacer que su audiencia pueda concluir de un tema complejo una idea simple y propia? En este taller práctico, en el que se incluyen estudios de casos y ejemplos prácticos, los participantes aprenderán técnicas interactivas para impartir información de una manera en la que su público se sentirá a la vez motivado e inspirado. Este taller está dirigido a educadores, capacitadores, científicos y activistas comunitarios que informan o lanzan debates sobre temas complejos.

Impartido por: Lisa Heft, San Francisco AIDS Foundation, USA; Juan Jacobo Hernandez, Colectivo Sol, Mexico; Ruth Gunn Mota, Public Health Institute, USA

SB 26  Advocacy: How to Influence Decision-Makers in Africa to Take Action
Venue: Room H
Time: 15.00-18.30

HIV/AIDS prevention, care and treatment strategies can only have lasting effect if the political leaders in our countries take strong positions of authority. In addition, leadership in the response to HIV/AIDS has to be built on compassion and responsibility. How do you influence leaders to take action or to change their current attitudes about the epidemic? In this workshop, participants will look at a variety of ways of influencing leadership in their country. It is best suited for those who are interested in advocacy and policy (both national- and state-level).

Facilitated by: Ron Machinist, National Council for International Health, USA; Allan Ragi, Kenya AIDS NGO Consortium, Kenya

NOTES

Pathway Symbol: Policy